Sun Pharma has announced its intention to acquire Innovcare Lifesciences in a deal valued at $28.7 million.

Sun Pharma has obtained a bridge loan to finance its $12 billion acquisition of Organon.

Evercore ISI reports that talk of a potential deal between Sun Pharma and Organon & Co. (OGN) lacks confirmation and remains speculative.

The generic drugmakers, with many more expected to make announcements, are eyeing a share of the market for Semaglutide in India, which is estimated to be $1 billion over the next couple of years

India's leading bank has committed $1 billion in funding to support Sun Pharma's acquisition deal in the United States.

India's Sun Pharma has announced its acquisition of the US-based pharmaceutical company Organon for approximately $12 billion. This deal represents one of the largest overseas pharma acquisitions for an Indian company.

Organon shares saw a jump in early trading after reports emerged of a potential bid from Sun Pharmaceutical.

India's Sun Pharma is set to enter the "big leagues" of the pharmaceutical industry following a significant $12 billion deal in the United States. This acquisition or partnership is expected to substantially expand its market presence and influence.

Organon's shares jumped 15% after Sun Pharma reportedly agreed to an $11.8 billion buyout deal. The acquisition news significantly boosted Organon's stock performance.

Organon's stock saw an increase following reports that Sun Pharma is close to a $12 billion buyout agreement for the company.